A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Open Access
- 1 December 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (23), 7940-7946
- https://doi.org/10.1158/1078-0432.ccr-08-0221
Abstract
Purpose: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models. A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer. Experimental Design: Patients with at least one prior systemic therapy and a rising prostate-specific antigen (PSA) were eligible. Patients received 17-AAG at a dose of 300 mg/m2 i.v. weekly for 3 of 4 weeks. The primary objective was to assess the PSA response. Secondary objectives were to determine overall survival, to assess toxicity, and to measure interleukin-6, interleukin-8, and maspin levels and quality of life. Results: Fifteen eligible patients were enrolled. The median age was 68 years and the median PSA was 261 ng/mL. Patients received 17-AAG for a median number of two cycles. Severe adverse events included grade 3 fatigue (four patients), grade 3 lymphopenia (two patients), and grade 3 back pain (two patients). The median PSA progression-free survival was 1.8 months (95% confidence interval, 1.3-3.4 months). The 6-month overall survival was 71% (95% confidence interval, 52-100%). Conclusions: 17-AAG did not show any activity with regard to PSA response. Due to insufficient PSA response, enrollment was stopped at the end of first stage per study design. The most significant severe toxicity was grade 3 fatigue. Further evaluation of 17-AAG at a dose of 300 mg/m2 i.v. weekly as a single agent in patients with metastatic, hormone-refractory prostate cancer who received at least one prior systemic therapy is not warranted.Keywords
This publication has 29 references indexed in Scilit:
- Endogenous Inhibition of Histone Deacetylase 1 by Tumor-Suppressive MaspinCancer Research, 2006
- RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patientsAnnals Of Oncology, 2005
- Tumor-suppressive Maspin Regulates Cell Response to Oxidative Stress by Direct Interaction with Glutathione S-TransferasePublished by Elsevier BV ,2005
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survivalThe Prostate, 2005
- Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancerThe Prostate, 2004
- Bax Mediates the Apoptosis-Sensitizing Effect of MaspinCancer Research, 2004
- Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancerUrologic Oncology: Seminars and Original Investigations, 2004
- Maspin is up‐regulated in premalignant prostate epitheliaThe Prostate, 2002
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989